ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BVXP Bioventix Plc

4,450.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4,450.00 4,400.00 4,500.00 4,450.00 4,450.00 4,450.00 16,374 07:47:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 12.82M 8.37M 1.6071 27.69 231.82M
Bioventix Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 4,450p. Over the last year, Bioventix shares have traded in a share price range of 3,450.00p to 5,060.00p.

Bioventix currently has 5,209,333 shares in issue. The market capitalisation of Bioventix is £231.82 million. Bioventix has a price to earnings ratio (PE ratio) of 27.69.

Bioventix Share Discussion Threads

Showing 1551 to 1574 of 1575 messages
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older
DateSubjectAuthorDiscuss
26/3/2024
09:53
Thx. Should have paid more attention in Maths at school :)
alter ego
26/3/2024
09:48
Looks like R-squared, so it's just an indication of how well the straight line fits the underlying data. Shame it wasn't a bit more exponential-ish.
stepone68
25/3/2024
23:00
?=9315. What value is ? Please
alter ego
25/3/2024
10:50
Yes .... thats a hell of a price jump as well. Pity the troponon sales fell a little short. Added a few this morn.
janeann
25/3/2024
10:39
I see Cavendish have raised their price target to 5900p from 4400p in Oct 23. Will be happy to see the BVXP once again climb above the Cavendish target price!
melody9999
25/3/2024
07:32
steady, points to competitive Alzheimer's environment with in-house mabs being developed by some IVD companies and alternative competition - market ought to be sufficiently large to support multiple competitors, temporary slowdown in troponin rate of adoption.
c3479z
13/3/2024
08:36
Half year results due later this month.
I expect another steady as she goes performance.
Suet

suetballs
01/3/2024
10:30
Hahaha, Blackhorse looking to invest his 'profits' from his investment in Watkins Jones WJG, I assume. Of course if he had been invested here - there would have been daily one line posts.
maddox
21/2/2024
15:36
the filtered ebonised equine makes an unwelcome appearance. No doubt spots an opportunity to talk its own book as ever.
alter ego
21/2/2024
14:28
Money moving to APH [LSE] , excellent growing health care company
blackhorse23
21/2/2024
10:49
Yes one heck of a rise since October last year.
Suet

suetballs
21/2/2024
10:34
Share price starting with a '5' now. Certainly feels like it is popular at the moment.
stepone68
16/2/2024
16:07
Something afoot?
Suet

suetballs
16/2/2024
15:22
maddox - all I can say is I can sell a shed load of these at 49.10 at present. someone still wants them

49.15 now!!

janeann
16/2/2024
11:31
So, we're hitting new All Time High's despite the Director sale; 4848p as I post. Anyone with Level 2 able to shed some light on the activity?
maddox
12/2/2024
15:36
Maddox... agree completey.... this has had plenty of strenght since Harrisons sale a could of weeks back. someone still wants them at 47.01!
janeann
12/2/2024
12:37
BVXP are in the running to develop what has been described as the 'Holy Grail' of diagnostic testing - an early stage Alzheimer's test.

BBC Radio 4 Today report on new Alzheimer's treatments. Mentions that there are about 28 dementia drugs in late stage development. Whilst the current two leading drugs show efficacy the promise is of better drugs being developed.

The need for an early stage diagnostic test is clear in this report. Arguably, it's equally as important to have a simple early stage test as the drugs.

maddox
12/2/2024
12:16
A Director's sale, if well handled, can work to enhance the share price - you sell sufficient shares to entice in a new Financial Investor - but not sell them as big a holding as they which to have. They then need to buy in the open market, creating demand and supporting the share price whilst they accumulate their desired holding.

Can't say whether this is the case here but looks likely.

maddox
05/2/2024
09:37
Looks like we are now back at an all time high - around the 4450 achieved 3 years ago, and there's been over £4 of divis since then as well.
stepone68
29/1/2024
15:58
Peter Harrison has sold £2.6 million worth of shares to a new institutional investor.
jurgenklopp
24/1/2024
09:15
well researched 1c3479z. You're correct. I had conformation from Peter Harrison this morning. It does however, show the potential of the work being done by BVXP in this field.
alter ego
23/1/2024
16:42
not convinced- the journal article refers to an ALZpath validated immunoassay, did ALZpath also provide the antibody?
in any case, should this be validated, one expects the BVXP pTau 217 might have advantages over mouse monoclonals and be commercially in high demand from various diagnostics companies eg Roche etc with a long life cycle.

1c3479z
23/1/2024
10:08
Can't be certain but it sounds like a BVXP SMA.

Sky news report today mentions " Measuring levels of a protein called p-tau217 in the blood...." "The study from Dr Nicholas Ashton at the University of Gothenburg, and colleagues, is published in the Jama Neurology journal."


From BVXP Annual Report for year ended 30/6/23

"A leading blood biomarker for “A” is a phosphorylated form of tau called pTau217. A prototype assay from Gothenburg using an SMA has now been established which has performed well with frozen patient samples from a number of different cohorts." and
"A novel blood-based prototype assay for neurodegeneration (N) using another Tau SMA has also been developed in Gothenburg. This work clearly supports the potential utility of this blood test and further work is ongoing in Gothenburg with further publications planned."

alter ego
23/1/2024
07:42
Is it definitely Bioventix's study being referred to? https://www.ft.com/content/92e081d0-d47b-4036-aac5-20b103b4729a
zebediah
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older

Your Recent History

Delayed Upgrade Clock